No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Foresee is a Taiwan and US-based biopharmaceutical company focused on two key areas: its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products for specialty markets, and its transformative preclinical and clinical first-in-class New Chemical Entity (NCE) programs targeting rare and severe disease areas with high unmet needs. Its product portfolio includes late and early-stage programs, with its lead product CAMCEVI® used for the treatment of advanced prostate cancer.
www.foreseepharma.comNo one on the platform currently holds 6576.TWO.
No tracked institution reports a position in 6576.TWO as of their last filing.
No one on the platform has traded 6576.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 3.0% | 13.4% | ||||
| Profit Margin % | -204.8% | -280.6% | ||||
| Free Cash Flow Margin % | -198.9% | -237.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $540M | -22.8% | $11.26 | $11.26–$11.26 | — | 1 |
| 2027 | $677M | +25.3% | $11.26 | $11.26–$11.26 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-03-13 | $-0.57 | $-0.92 | -61.4% |
| 2025-11-13 | $-1.76 | $-0.74 | +58.0% |
| 2025-08-13 | $-1.28 | $-2.14 | -67.2% |
| 2025-05-07 | $-1.35 | $-1.90 | -40.7% |
| 2025-02-19 | $-1.38 | $-1.45 | -5.3% |
| 2024-11-14 | $-1.67 | $-2.25 | -34.7% |
| 2024-08-14 | $-1.40 | $-1.21 | +13.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 6576.TWOForesee Pharmaceuticals Co., Ltd. | $82.80 | +1.10% | $13.0B | — |
| 1720.TWStandard Chem & Pharm Co. Ltd. | $55.90 | -0.36% | $11.0B | — |
| 1789.TWScinoPharm Taiwan, Ltd. | $18.15 | +0.28% | $14.4B | — |
| 3218.TWOUniversal Vision Biotechnology Co., Ltd. | $133.50 | +0.38% | $11.3B | — |
| 3705.TWYungShin Global Holding Corporation |
| $56.00 |
| +0.00% |
| $14.9B |
| — |
| 4129.TWOUnited Orthopedic Corporation | $82.40 | -0.24% | $7.9B | — |
| 4736.TWTaiDoc Technology Corporation | $130.00 | +0.78% | $12.4B | — |
Source: Financial Modeling Prep · peers by sector/industry